ArticleLaryngoscope investigative otolaryngology2025
Trends of Adjuvant Radiation After TORS in Clinically Node Negative Oropharyngeal Cancer.
Article in Laryngoscope investigative otolaryngology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends of Adjuvant Radiation After TORS in Clinically Node Negative Oropharyngeal Cancer.Laryngoscope investigative otolaryngology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Frequency of adjuvant treatment for clinically node negative (cN0) oropharyngeal cancer (OPC) patients, candidates for single modality treatment, is not well established. We aimed to determine the rate and clinical predictors of adjuvant radiation therapy (aRT) among cT1-T2 N0 patients undergoing transoral robotic surgery (TORS). Methods: The National Cancer Database was retrospectively reviewed for cT1-T2 N0 OPC patients who received TORS as definitive treatment between 2010 and 2017. Demographic, oncologic data, and the proportion of patients receiving aRT were collected. Multivariable logistic regression was performed to determine clinical predictors of aRT. Adjusted Odds Ratios (aOR) with 95% Confidence Intervals (95% CI) were calculated. Results: 1173 cN0 OPC patients underwent TORS (mean age 62 ± 9 years). 95% of patients were pT1-T2 and 59% were pN0. Overall, 29% of patients received aRT, including 21% of cT1 patients and 37% of cT2 patients. 32% of patients with tonsil/lateral pharyngeal wall and 29% with base of tongue tumors received aRT. Among those with negative margins, 25% received aRT. Positive margins (aOR 4.0, 95% CI 2.7-5.8), base of tongue subsite (aOR 2.7, 95% CI 1.5-4.7), and salivary gland malignancies (aOR 2.9, 95% CI 1.6-5.3) had an increased likelihood of adjuvant RT. Compared to pT1 patients, pT2 was associated with receiving adjuvant RT (aOR 1.9, 95% CI 1.4-2.6). HPV status was not a significant predictor of aRT. Conclusion: Nationally, most cT1-T2 N0 OPC patients undergoing TORS ultimately do not receive adjuvant radiation therapy, thus representing excellent candidates for single-modality treatment in most cases. Level of Evidence: N/A.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.